Evotec (NASDAQ:EVO) Trading Down 4.4%

Evotec SE (NASDAQ:EVO - Get Free Report) shares were down 4.4% during trading on Thursday . The company traded as low as $4.88 and last traded at $4.98. Approximately 19,572 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 111,222 shares. The stock had previously closed at $5.21.

Get Evotec alerts:

Analyst Upgrades and Downgrades

EVO has been the topic of a number of research analyst reports. HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of Evotec in a research note on Thursday, May 23rd. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a "buy" rating to a "hold" rating in a report on Thursday.

View Our Latest Stock Analysis on EVO

Evotec Stock Performance

The company's fifty day moving average is $4.91 and its 200 day moving average is $6.83. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.86 and a quick ratio of 1.79.

Hedge Funds Weigh In On Evotec

Several institutional investors and hedge funds have recently bought and sold shares of the business. Quadrant Capital Group LLC acquired a new position in Evotec in the fourth quarter valued at about $25,000. Cetera Advisors LLC bought a new stake in Evotec in the 1st quarter valued at $188,000. Optiver Holding B.V. raised its holdings in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company's stock valued at $945,000 after acquiring an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC acquired a new position in shares of Evotec during the 4th quarter worth $53,931,000. Hedge funds and other institutional investors own 5.81% of the company's stock.

Ad DTI

[INSIDE] “Stock hotsheets” with exact trading dates

Imagine having a “trading calendar” with what could be the EXACT dates to buy and sell some of your favorite stocks… I’m talking about popular stocks like Apple, Walmart and even Google! Imagine being able to hone in on the only days of the year that our backtesting has found are historically shown to yield the BIGGEST opportunities... With these unique sheets in your hands, designed to help you decide when to confidently enter AND exit trades... Sounds crazy? The crazy thing is that this ability exists RIGHT NOW.

You can see what I mean when you click right here

About Evotec

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.

Should you invest $1,000 in Evotec right now?

Before you consider Evotec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.

While Evotec currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report